Sarepta stock: buy or sell?

SRPT stock price: $128.34 3.37% At close on June 26th, 2019

Updated on:
June 26th, 2019

2

After sliding for 4 sessions, Wednesday Sarepta skyrocketed a brilliant 3.37%, closing at $128.34. Last session broke a streak of 4 red days. On Jun 17th SRPT rocketed a super good 5.90%.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases.

Should I buy Sarepta stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

Check the only buy setup that matches with Sarepta stock now:

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MAYes
100d MA crossing up 200d MANo

Is Sarepta Therapeutics stock a buy?

Banks and financial institutions publish stock ratings everyday. At Stocks2.com, we detected 14 ratings published for SRPT stock in the last 30 days.

The general sentiment of these ratings is bullish for SRPT stock, with 13 positive ratings.
Is SRPT a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-6-17HC Wainwrightn/aBuy
2019-5-9Royal Bank of Canadan/aOutperform
2019-5-16Citigroupn/aBuy
2019-5-14Morgan Stanleyn/aOverweight
2019-3-4Morgan StanleyOverweightOverweight
2019-3-28Piper Jaffray Companiesn/aOverweight
2019-3-12BMO Capital Marketsn/aOutperform
2019-3-11Credit Suisse Groupn/aOutperform
2019-3-1CitigroupBuyBuy
2019-2-28Nomuran/aBuy
2019-2-28Cantor FitzgeraldOverweightPositive
2019-2-27JMP Securitiesn/aBuy
2019-2-22Cantor Fitzgeraldn/aBuy
2019-1-17Royal Bank of Canadan/aOutperform

Sarepta stock analysis

Daily outlook

After sliding for 4 sessions, Wednesday Sarepta skyrocketed a brilliant 3.37%, closing at $128.34.

After sliding for 4 days, Wednesday Sarepta skyrocketed a brilliant 3.37%, closing at $128.34. Today SRPT price bounced up over the SMA of 200 days demonstrating to be a significant support for this stock. SRPT shows a short term strength with several rising tops and rising bottoms. In the very short term, yesterday it marked a new bottom at $123.79 that should act a support if Sarepta starts a trading flat base in the range of $123.79 - $135.71 If Sarepta Therapeutics breakouts over $135.71 with average or higher volume, this would be a signal that the uptrend resumes.

SRPT stock chart (daily)

Weekly outlook

After boosting a dazzling 7.94% in a week last week, Sarepta Therapeutics closed this week at $128.34 and decreased an unpleasant -1.19%. Late May SRPT plunged a bloodcurdling -6.14% in just one week.

Since last week when SRPT stock price broke up the SMA40w line, it gained $8.77 (7.33%).

SRPT stock chart (weekly)

Sarepta stock price history

Sarepta stock went public on June 4th, 1997 with a price of $42.751. Since then, SRPT stock surged a 200.20%, with a yearly average of 9.10%. If you had invested right after SRPT's IPO a $1,000 in Sarepta stock in 1997, it would worth $2,002.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Sarepta stock historical price chart

SRPT stock reached 52-week highs on October at $165.87, and all-time highs 2018-06-19 with a price of 176.5.

Sarepta stock price target is $207.50

How much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. We have 12 price forecasts for SRPT stock released in the last 30 days:
SRPT stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-6-17HC WainwrightSet Price Targetn/a$267.00-
2019-5-9Royal Bank of CanadaLowers Target$191.00$188.00-1.6%
2019-5-16CitigroupLowers Target$201.00$190.00-5.5%
2019-5-14Morgan StanleyLowers Target$169.00$165.00-2.4%
2019-3-4Morgan StanleyRaises Target$161.00$169.005%
2019-3-28Piper Jaffray CompaniesRaises Target$200.00$208.004%
2019-3-11Credit Suisse GroupReiterates$189.00$207.009.5%
2019-3-1CitigroupRaises Target$188.00$201.006.9%
2019-2-28NomuraRaises Targetn/a$230.00-
2019-2-28Cantor FitzgeraldReiteratesn/a$231.00-
2019-2-27JMP SecuritiesReiteratesn/a$270.00-
2019-1-17Royal Bank of CanadaReiteratesn/a$164.00-
(in average)$185.60$207.5012.0%
The price prediction for Sarepta Therapeutics stock is $207.50, moving in a range between $270.00 and $164.00. In average, analysts' outlook on SRPT price target is positive, increasing the target by a 12.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On February, Sarepta Therapeutics reported its latest financial data, posting an astounding growth for the Earnings per Share (EPS). Experts expected $-1.08 per share, but Sarepta posted $-2.05.
SRPT earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a0.05n/a
2017-Q2-n/a-1.11n/a
2017-Q32017-10-25-0.85-0.78n/a
2017-Q42018-03-01-0.31-0.37n/a
2018-Q12018-05-03-0.48-0.44n/a
2018-Q22018-08-08-0.68-0.66n/a
2018-Q32018-10-24-0.86-1.15n/a
2018-Q42019-02-27-1.08-2.05n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

In 2018, Sarepta Therapeutics annual sales climbed an exceptional 94.74% to $301.03 million USD from $154.58 marked in 2017. On the other hand, its earnings margin (compared to sales) collapsed to -120.22%, that is $-361.92 million.

SRPT annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$14 M-$-111.99 M-787.6%-
2014$9.76 M-31.39%$-135.79 M-1391.7%21.25%
2015$1.25 M-87.16%$-220.03 M-17560.3%62.04%
2016$5.42 M332.64%$-267.27 M-4930.2%21.47%
2017$155 M2,751.58%$-50.69 M-32.8%-81.03%
2018$301 M94.74%$-361.92 M-120.2%614.01%

Quarterly financial results

Sarepta Therapeutics reported $84.42 M in sales for 2018-Q4, a 7.55% improvement compared to previous quarter. Reported quarter earnings marked $-140.90 million with a profit margin of -166.91%. Profit margin plummed a -69.57% compared to previous quarter when profit margin was -97.33%. When comparing sales to same quarter last year, Sarepta sales marked a super good increase and rocketed a 47.38%. Looking back to recent quarterly results, Sarepta Therapeutics posted 7 positive quarters in a row.
SRPT quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q1$16 M-$84.09 M514.6%-
2017-Q2$35 M114.26%$-63.05 M-180.1%-174.98%
2017-Q3$46 M31.25%$-47.73 M-103.9%-24.30%
2017-Q4$57 M24.65%$-24.00 M-41.9%-49.72%
2018-Q1$65 M12.79%$-35.36 M-54.7%47.36%
2018-Q2$74 M13.81%$-109.27 M-148.6%208.99%
2018-Q3$78 M6.74%$-76.39 M-97.3%-30.09%
2018-Q4$84 M7.55%$-140.90 M-166.9%84.43%

Sarepta ownership

When you are planning to buy a company, it's always worth to review its ownership structure.

Sarepta shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 5.25% of all shares.

Bearish positions for SRPT stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Sarepta:

SRPTALNYBCRXGILDHEB
Market cap$9.5 B$7.4 B$390.5 M$84.7 B$418.3 M
Total shares74.2 M106.5 M110.3 M1,270.0 M96.8 M
Float shares70.3 M105.6 M60.2 M1,270.0 M1.8 M
  - Institutional holdings (%)92.5%88.2%93.6%82.6%6.1%
  - Insider holdings (%)5.2%10.8%1.0%0.7%12.8%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

Sarepta summary

Wednesday, June 26th, 2019
Open$124.89
Close$128.34
Day range$124.61 - $129.43
Previous close$124.16
Session gain3.37%
Average true range$4.93
50d mov avg$120.66
100d mov avg$125.88
200d mov avg$126.90
Daily patternlb03a
Weekly pattern lt11a

Sarepta performance

To better understand Sarepta Therapeutics performance you must compare its gains with other related stocks in same sector or industry. We chose Alnylam Pharmaceuticals, BioCryst Pharmaceuticals, Gilead Sciences, Hemispherx BioPharma, Ionis Pharmaceuticals, NewLink Genetics, PTC Therapeutics and Retrophin as the bechmarking frame for Sarepta stock.
Stock3m6m12m
SRPTSarepta Therapeut...7.68%18.99%-2.91%
ALNYAlnylam Pharmaceu...-25.64%-1.29%-29.44%
BCRXBioCryst Pharmace...-56.51%-55.08%-38.22%
GILDGilead Sciences3.54%9.83%-2.50%
HEBHemispherx BioPha...-38.64%-48.33%-69.32%
IONSIonis Pharmaceuti...-21.66%23.81%52.60%
NLNKNewLink Genetics-19.17%6.85%-67.23%
PTCTPTC Therapeutics9.88%29.21%22.62%
RTRXRetrophin-12.95%-11.58%-27.73%

Sarepta competitors

One check before trading any stock is to have a look a list of its competitors, in this case for Sarepta Therapeutics. We picked 8 companies as Sarepta Therapeutics competitors as they are in the same industry or have similar market objectives.

Latest Sarepta stock news